Investigate the causality and genetic association between

migraine and Parkinson's disease

1

3	
4	Ming-Gang Deng ^{1,2,†} , Xiuxiu Zhou ^{1,2,†} , Fang Liu³, Kai Wang⁴, Lingli Luo⁵, Min-Jie Zhang³, Qianqian Feng³,
5	Jiewei Liu ^{1,2}
6	
7	¹ Department of Psychiatry, Wuhan Mental Health Center, Wuhan 430012, Hubei, China
8	² Department of Psychiatry, Wuhan Hospital for Psychotherapy, Wuhan 430012, Hubei, China
9	³ School of Public Health, Wuhan University, Wuhan 430071, Hubei, China
10	⁴ Department of Public Health, Wuhan Fourth Hospital, Wuhan 430033, Hubei, China
11	⁵ Department of Pathophysiology, School of Basic Medicine and Tongji Medical College, Huazhong
12	University of Science and Technology, Wuhan, 430030, China
13	
14	[†] These authors contributed equally to this work.
15	
16	*Correspondence to: Ming-Gang Deng (deng.minggang@outlook.com)
17	Jiewei Liu (liujiewei@hust.edu.cn)

Abstract

18

19

20

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

Background: The relationship between migraine and Parkinson's disease (PD) remains controversial. We

intend to investigate the causal and genetic association between migraine and PD.

21 **Methods:** Data related to migraine [any migraine (AM), migraine without aura (MO), and migraine with

aura (MA)] and PD were respectively obtained from the latest Genome-wide meta-analysis conducted by

the International Headache Genetics Consortium and the International Parkinson's Disease Genomics

Consortium. Univariate Mendelian Randomization (UMR) and multivariate MR (MVMR) were conducted

to estimate their bidirectional causality, and global/local genetic correlation and tissue expression analyses

were utilized to assess their genetic associations.

Results: The UMR presented that AM (OR: 1.016, 95% CI: 0.908-1.135, p = 0.785), MO (OR: 0.944, 95% CI:

0.836-1.067, p = 0.358) and MA (OR: 1.006, 95% CI: 0.951, 1.064, p = 0.846) were unlikely to be associated

with PD risk. Similarly, the reverse UMR analyses demonstrated that PD was unrelated to the risks of

migraine and its subtypes. These null associations were supported by the MVMR when adjusted for

coronary heart disease and hypertension. The global genetic correlation analyses presented that AM (r_g =

-0.061, p = 0.127), MA ($r_g = -0.047$, p = 0.516), MO ($r_g = -0.063$, p = 0.492) were generally not related to

PD, and the local genetic correlation analyses shown they were also uncorrelated in any region.

Additionally, the tissue expression analyses found they had no shared tissues.

Conclusion: This study suggested no causality or association between migraine and PD from the genetic

perspective.

Keywords: Migraine; Parkinson's disease; Causality; Genetic association.

1. Introduction

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Migraine is a highly prevalent brain disorder characterized by recurrent headache attacks, often accompanied by symptoms such as photophobia, phonophobia, nausea, and vomiting¹. According to whether the attack was preceded by an aura, migraine could be further classified into migraine without aura (MO) and migraine with aura (MA)1. Recent studies have confirmed that migraine is bi-directionally related to the risk of multiple diseases including major depressive disorder², epilepsy³, coronary artery disease4, etc. Parkinson's disease (PD) is a chronic progressive neurodegenerative movement disorder characterized by a profound and selective loss of nigrostriatal dopaminergic neurons⁵. Considering the shared involvement that has been reported among neurotransmitters, the brainstem, and hypothalamic regions in both migraine and PD, many epidemiology studies explored their relationship but have not obtained consent yet. Some studies concluded that migraine was not related to the risk of PD⁶⁻⁸, nevertheless, recent studies found people with migraine were more susceptible to suffering from PD9,10. Meanwhile, Nunes et al. demonstrated that PD patients had a lower lifetime prevalence of headache than controls¹¹, and a multicenter case-controlled study found the overall headache and migraine severity reduced after PD onset12, which together suggested a potential causal effect of PD on migraine. Therefore, the recent meta-analysis stated that the exact causal relationship between migraine and PD was still ambiguous¹³. Migraine and PD have both been reported to have substantial genetic backgrounds^{14,15}, and the recent genome-wide association studies (GWASs) have identified plenty of genome-wide significant genetic variations related to migraine 16,17 and PD18, which provided an opportunity to investigate their relationship from the genetic perspective. Mendelian Randomization (MR), which uses genetic variants associated with specific exposures as the instrumental variables, could overcome the limitations of conventional observational studies such as reverse causality and residual confusion¹⁹ to provide a more robust causal

estimate of exposures on outcomes because germline genetic variants are randomly inherited from parents to offspring²⁰. Therefore, we would like to utilize MR to examine the bidirectional causal relationship between migraine and PD based on the GWAS summary statistics. Genetic correlation and tissue enrichment analyses were also conducted to seek their genetic associations. We hypothesize that migraine and PD were not correlated from the genetic perspective based on current data.

2. Methods

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

2.1. Data sources

This study is designed to investigate the bidirectional causal relationship and the genetic association between migraine and PD, an overview of this study design is presented in **Supplementary Fig. 1**. Genetic variants associated with any migraine (AM) were obtained from the latest Genome-wide meta-analysis by Hautakangas et al¹⁶, which included a total of 102,084 cases and 771,257 controls from the International Headache Genetics Consortium (IHGC)-2016¹⁷, 23andMe, UK Biobank, GeneRISK, and Nord-Trøndelag Health Study. In this meta-analysis, migraine was defined as self-reported or based on the International Classification of Headache Disorders second edition criteria. Due to the data release policy, we retrieved the summary-level statistics with the samples from 23 and Me being excluded, and this elimination resulted in a subsample of 589,356 (48,975 cases and 540,381 controls). Additionally, to evaluate the relationship between PD and migraine subtypes [migraine without aura (MO) and migraine with aura (MA)], genetic data were obtained from the IHGC-2016¹⁷. MO participants consisted of 8,348 cases and 139,622 controls from 11 studies from the Danish Headache Center, German migraine without aura, etc. MA samples composed of 6,332 cases and 144,883 controls from 12 studies including Danish Headache Center, Dutch Migraine with aura, Nord-Trøndelag Health Study, etc. Detailed information can be found in the original paper¹⁷.

PD associated genetic variants were obtained from the International Parkinson's Disease Genomics Consortium¹⁸, which included 37,688 cases, 18,618 UK Biobank proxy cases, and about 1.4 million controls from 17 cohorts. As GWAS results of several datasets (such as 23andMe) were not publicly available, genome-wide associations of 33,674 cases and 449,056 controls were used in this study.

2.2. Mendelian Randomization

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

To ensure the causal estimates from the MR are valid, the genetic variants should satisfy three critical assumptions: (1) the relevance assumption indicates the genetic variants are strongly associated with the exposure, (2) the independence assumption implies genetic variants are not associated with any potential confounder of the exposure-outcome association and (3) the exclusion restriction assumption refers that variants do not affect outcome independently of exposure²¹. For the bidirectional MR causal estimates, the analyses were performed in two directions with genetic variants with migraine (1) as exposure: to evaluate whether individuals suffered from migraine were more likely to develop PD, and (2) as outcome: to assess whether people with PD were less likely to report migraine. The procedures of instrument selection in our study were in line with the aforementioned three critical assumptions. For the relevance assumption, SNPs were initially screened at genome-wide significance (P $< 5 \times 10^{-8}$), and if no SNP were discovered, this threshold was loosened to $P < 1 \times 10^{-5}$ as previous studies did^{2,22}. To avoid the bias triggered by weak instruments, the F statistic was calculated and SNPs with an F statistic lower than 10 were considered as weak instruments and excluded^{23,24}. For the exclusion restriction assumption, the retained SNPs were clumped for linkage disequilibrium (LD) with the European samples from the 1000 Genomes Project²⁵ as the reference panel using the PLINK tool (version 1.9)²⁶. The clumping R² cut-off was set as 0.001 within a window of 10 Mb. If an obvious LD effect was detected, only the SNP with the lowest p-value would be kept. Additionally, the modified Cochran's Q test²⁷ was performed to identify outlier pleiotropic SNPs as the Q statistic much larger than N_{SNP}-1 suggests violation of independence or exclusion restriction assumption²⁸, and these outlier pleiotropic SNPs would be excluded. As for the independence assumption, we used the PhenoScanner V2 tool²⁹ to assess whether the selected SNPs were related to the confounders or risk factors in the relationship between migraine and PD. If obvious confounders were identified, they would be further adjusted in the multivariate MR (MVMR) analyses, which is an extension of MR that can detect the causal effects of multiple risk factors jointly³⁰. The inverse variance weighted (IVW) method was adopted as the primary method to infer the causal relationship between migraine and PD, which used a meta-analysis approach that combined the Wald estimate for each SNP to obtain an overall estimate and was the most efficient method when average pleiotropic effect did not exist. Additionally, three well-established and horizontal pleiotropy robust methods including MR-Egger, weighted median, and MR-PRESSO (Pleiotropy RESidual Sum and Outlier) were supplemented to validate the IVW estimates. Sensitive analyses by the MR-Egger regression intercept and leave-one-out analyses were respectively conducted to check whether directional horizontal pleiotropy or a single SNP was driving the results of MR analyses. The MR analyses were performed in R software (version 4.3.1) with TwoSampleMR (version 0.5.7), MendelianRandomization (version 0.8.0), MRPRESSO (version 1.0), and RadialMR (version 1.1) packages.

2.3. Genetic association analyses

2.3.1. Global Genetic Correlation

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

The LD score regression³¹, which could evaluate the genetic heritability correlation cross traits based on GWAS summary statistics, was adopted to evaluate the genetic correlation (r_g) between migraines and PD, with European ancestry samples from the 1000 Genomes Project being the reference panel²⁵. This procedure was performed in R software (version 4.3.1) with the *ldscr* (version 0.1.0) package.

2.3.2. Local Genetic Correlation

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

148

To investigate whether migraine and PD were locally correlated at a defined genomic region, ρ -HESS (Heritability Estimation from Summary Statistics)^{32,33}, which was a software package for estimating and visualizing local SNP-heritability and genetic correlation from GWAS summary association data, was utilized. In this algorithm, the entire genome was partitioned into 1703 independent regions across all chromosomes (sex chromosomes excluded) based on the European population LD patterns. The local genetic correlation between migraine and PD was quantified in particular regions, and the Bonferroni corrected P-value of P < 0.05/1703 was set as the significance threshold.

2.3.3. Tissue expression analyses

To explore whether the GWAS data related to migraine and PD were enriched in some specific and same tissues, we implemented the MAGMA (Multi-marker Analysis of GenoMic Annotation)³⁴ in FUMA³⁵ (https://fuma.ctglab.nl/) to perform the tissue expression analyses, which was based on the expression data from 54 tissues of GTEx V8³⁶. The maximum p-value of lead SNPs was set as $P < 5 \times 10^{-8}$, and if no SNP met this criterion, we loosened it to $P < 1 \times 10^{-5}$. The upstream and downstream windows size of genes to assign SNPs were set to 35 and 10kb^{37} , respectively. The other parameters and settings were used default. Bonferroni correction was applied and a p-value threshold of p < 0.05/54 was set to obtain significant findings.

3. Results

3.1. Mendelian Randomization

3.1.1. Univariate Mendelian Randomization

147 The selected instrumental variants based on prior criteria were presented in **Supplementary Table 1-2**.

The total proportion of variance explained by their corresponding data sets ranged from 3.986% to

149 21.772%.

The results of MR causal inference between migraine and PD are illustrated in **Table 1**. The IVW method presented that genetically predicted liability to AM (OR: 1.016, 95% CI: 0.908-1.135, P = 0.785), MO (OR: 0.944, 95% CI: 0.836-1.067, P = 0.358) and MA (OR: 1.006, 95% CI: 0.951-1.064, P = 0.846) were unlikely to be associated with PD risk. Regarding the reverse association, the IVW method also demonstrated that PD was not related to the risk of AM (OR: 1.003, 95% CI: 0.975-1.032, P = 0.817), MO (OR: 0.956, 95% CI: 0.893-1.025, P = 0.207) and MA (OR: 1.032, 95% CI: 0.955-1.115, P = 0.430). These null associations were generally supported by the supplemented analyses by MR-Egger, weighted median, and MR-PRESSO methods. The scatter plot of SNP effects on migraine versus PD, and PD versus migraine was presented in **Supplementary Fig. 2**. Sensitive analyses by the MR-Egger regression intercept showed there was no directional horizontal pleiotropy affecting the overall causal estimates (**Table 1**) and leave-one-out analyses implied the overall effect was not driven by a single SNP (**Fig. 2**).

3.1.2. Multivariate Mendelian Randomization

for the confounding effect of hypertension.

As shown in **Supplementary Table S1-S2**, genetic variants associated with migraine were meanwhile related to coronary heart disease and hypertension, which have been demonstrated as risk factors of PD^{38,39}, while no obvious confounding phenotypes were identified in genetic variants related to PD. Therefore, we performed MVMR analyses to control the influence of coronary heart disease and hypertension and the result is presented in **Table 2**.

After adjustment for coronary heart disease, the IVW method indicates AM (OR: 0.993, 95% CI: 0.895-1.102, P = 0.897), MO (OR: 0.942, 95% CI: 0.857-1.034, P = 0.207), and MA (OR: 0.996, 95% CI: 0.931-1.066, P = 0.902) were not associated with PD risk, and reversely PD was also not correlated with migraine risks. This bidirectional null association was supported by the results found by MR-Egger, weighted median, and MR-PRESSO methods. Similarly, migraine was not associated with PD risk and vice-versa when controlled

3.1.3. Assessment of assumptions

Firstly, for the relevance assumption, instrumental variables related to migraine and PD were selected from the recent GWASs with large sample sizes, and SNPs with an F statistic of less than 10 were excluded, thus making it unlikely to induce weak instrument bias. Secondly, for the independence assumption, the selected SNPs were identified to be related to coronary heart disease and hypertension, which were the confounding factors in the association between migraine and PD. To avoid this bias, we performed the MVMR to control the confounding effect, and the association between migraine and PD was still robust. Thirdly, for the exclusion restriction assumption, we clumped SNPs at a restricted standard to make the SNPs independent of each other, and modified Q tests were conducted to identify the outlier pleiotropic SNPs. Besides, the MR-Egger regression intercept term indicated there was no significant horizontal pleiotropy among the instruments.

3.2. Genetic association analyses

Although no obvious causality was found between migraine and PD, we further attempted to investigate whether they were genetically correlated via global/local genetic correlation and tissue expression analyses.

3.2.1. Global Genetic Correlation

We used LDSC to investigate the global genetic correlation between PD and migraine based on their corresponding GWAS summary statistics. The LD score regression showed that AM (r_g = -0.061, P = 0.127), MA (r_g = -0.047, P = 0.516), MO (r_g = -0.063, P = 0.492) were generally not related to PD based on GWASs results.

3.2.2. Local Genetic Correlation

Although we didn't observe a significant genetic correlation between PD and migraine (including AM, MA, and MO), we then tested whether PD had a genetic correlation with migraine locally. We used ρ -HESS to

investigate the local genetic correlation between PD and migraine. The results of local genetic correlation analyses between AM and PD are presented in **Fig. 2** and **Supplementary Table S3**. After correcting for multiple testing (*P* < 0.05/1703), no significant local genetic correlation between AM and PD was observed. As for the migraine subtypes, we discovered MO and PD (**Supplementary Fig. 3 and Supplementary Table S4**) or MA and PD (**Supplementary Fig. 4 and Supplementary Table S5**) were also not locally correlated in any specific genomic region.

3.2.3. Tissue expression analyses

The tissue expression analyses showed GWAS associations related to AM were significantly enriched in colon sigmoid tissue, while GWAS data related to PD were significantly enriched in 6 brain tissues, with the most significant enrichment in Frontal Cortex BA9 (**Fig. 3**). However, genetic data related to MO and MA were not enriched in any GTEx v8 tissue (**Supplementary Fig. S5**). Based on the above results, we discovered that the expression of migraine and PD did not share any same tissue.

4. Discussion

Using the latest and largest GWAS summary data related to migraine and PD, we assessed their bidirectional causality via the univariate and multivariate MR analyses but failed to support their causal relationship. We further investigated their genetic association through the global/local genetic correlation and tissue expression analyses, and the results indicated migraine and PD were unlikely to be genetically correlated.

Previous observational studies have tried to investigate the relationship between migraines and PD⁶⁻¹³, but the sample size was relatively limited and the findings were contradictory. The possible mechanism to support the relationship between migraine and PD is mainly reflected in dopaminergic pathways. It was suggested that people who suffered from migraine had chronic dopaminergic hypofunction and dopamine receptor hypersensitivity^{10,40}, and the degeneration of dopamine neurons in dopaminergic

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

pathways is the key hallmark of PD^{15,41}. In this study, we aimed at exploring the causality and genetic relationship between migraine and PD based on GWAS results. Our MR and genetic correlation analyses didn't support a significant causality and genetic relationship between migraine and PD. A possible explanation is that over 200 genes that participate in broad dopaminergic pathways⁴², migraine, and PD may be affected by different genes among these genes to dysregulate dopaminergic pathways. Our study has several strengths that are worth pointing out. First of all, our GWAS data related to migraine and PD both came from the recent large-scale surveys, the sample sizes of which were much larger than previous observational studies. In addition, the associations between PD and migraine subtypes were investigated in this study, which was neglected by previous research. Furthermore, the MR and genetic association analyses could avoid reverse causality and confounding bias from conventional epidemiology studies. Despite the above advantages, the findings from our study should be interpreted within the context of several limitations. For example, the GWAS sample size of PD and migraine needs further extension, e.g., the 23andMe samples are not included in publicly available GWAS summary statistics due to the data release policy of 23andMe^{16,18}. Besides, GWASs could only capture common genetic variations that related to diseases, variations like copy number variations^{43,44} and rare mutations^{45,46} were not included, which are also important components of the genetic architecture of diseases. Lastly, the genetic data we used are largely Europeans, further GWASs of PD and migraine performed in non-European populations are warranted to confirm our results in this study. To sum up, we performed a series of analyses including MR, genetic correlation, and tissue enrichment analyses to investigate the causal and genetic relationship between migraine and PD based on their GWAS datasets. Our result didn't find clues for the relationship between migraine and PD by current GWAS results, however, this conclusion needs further confirmed in larger sample GWASs and different ethnic groups.

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

5. Contributors J.L. designed the study and edited the manuscript. M.-G.D. designed the study, performed the statistical analysis, and drafted the manuscript. X.Z. drafted and edited the manuscript. F.L., K.W., L.L., M.-J.Z., and Q.F. reviewed and edited the manuscript. 6. Declaration of Interests All authors declare no financial or non-financial competing interests. 7. Acknowledgments We acknowledge the participants from the International Headache Genetics Consortium. 8. Data Sharing Statement GWAS summary statistics for migraine and subtypes were available at International Headache Genetics Consortium (http://www.headachegenetics.org/), and Parkinson's disease associated data could be obtained from the International Parkinson's Disease Genomics Consortium (https://www.pdgenetics.org/). 9. Funding This study received no funding. 10. Ethics approval The data sets used were all public available, and the ethical approvals were obtained in the original papers. 11. Consent to participate/publish Not applicable. 12. Reference Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia: an international journal of headache. Jan 2018;38(1):1-211. doi:10.1177/0333102417738202

- 264 2. Choi KW, Chen CY, Stein MB, et al. Assessment of Bidirectional Relationships Between Physical Activity
- 265 and Depression Among Adults: A 2-Sample Mendelian Randomization Study. JAMA psychiatry. Apr 1
- 2019;76(4):399-408. doi:10.1001/jamapsychiatry.2018.4175 266
- 267 Altamura C, Corbelli I, de Tommaso M, et al. Pathophysiological Bases of Comorbidity in Migraine.
- 268 Frontiers in human neuroscience. 2021;15:640574. doi:10.3389/fnhum.2021.640574
- 269 Daghlas I, Guo Y, Chasman DI. Effect of genetic liability to migraine on coronary artery disease and
- 270 atrial fibrillation: a Mendelian randomization study. European journal of neurology. Mar 2020;27(3):550-
- 271 556. doi:10.1111/ene.14111
- 272 Thomas B, Beal MF. Parkinson's disease. Human molecular genetics. Oct 15 2007;16 Spec No. 2:R183-
- 94. doi:10.1093/hmg/ddm159 273
- 274 van Hilten JJ. The migraine-dopamine link: do migraine and Parkinson's disease coexist? Clinical
- Neurology and Neurosurgery. 1992/01/01/ 1992;94:168-170. doi:https://doi.org/10.1016/0303-275
- 8467(92)90060-G 276
- 277 Lorentz IT. A Survey of Headache in Parkinson's Disease. Cephalalgia: an international journal of
- 278 headache. 1989;9(2):83-86. doi:10.1046/j.1468-2982.1989.0902083.x
- 279 8. Sampaio Rocha-Filho PA, Leite Souza-Lima CF. Parkinson's Disease and Headaches: A Cross-Sectional
- 280 Study. Headache. May 2020;60(5):967-973. doi:10.1111/head.13815
- 281 Scher AI, Ross GW, Sigurdsson S, et al. Midlife migraine and late-life parkinsonism: AGES-Reykjavik
- 282 study. Neurology. Sep 30 2014;83(14):1246-52. doi:10.1212/wnl.0000000000000840
- 10. Wang HI, Ho YC, Huang YP, Pan SL. Migraine is related to an increased risk of Parkinson's disease: A 283
- 284 population-based, propensity score-matched, longitudinal follow-up study. Cephalalgia: an international
- journal of headache. Dec 2016;36(14):1316-1323. doi:10.1177/0333102416630577 285
- 286 11. Nunes JC, Costa Bergamaschi EN, Freitas FC, et al. Prevalence of headache in patients with Parkinson's
- 287 disease and its association with the side of motor symptom onset. Neurological sciences: official journal
- 288 of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. Apr
- 289 2014;35(4):595-600. doi:10.1007/s10072-013-1571-x
- 290 12. Suzuki K, Okuma Y, Uchiyama T, et al. The prevalence, course and clinical correlates of migraine in
- 291 Parkinson's disease: A multicentre case-controlled study. Cephalalgia: an international journal of headache.
- 292 Aug 2018;38(9):1535-1544. doi:10.1177/0333102417739302

- 293 13. Angelopoulou E, Papadopoulos AN, Spantideas N, Bougea A. Migraine, Tension-Type Headache and
- 294 Parkinson's Disease: A Systematic Review and Meta-Analysis. Medicina (Kaunas, Lithuania). Nov 20
- 295 2022;58(11)doi:10.3390/medicina58111684
- 14. Gervil M, Ulrich V, Kaprio J, Olesen J, Russell MB. The relative role of genetic and environmental factors 296
- 297 in migraine without aura. Neurology. Sep 22 1999;53(5):995-9. doi:10.1212/wnl.53.5.995
- 298 15. Kalia LV, Lang AE. Parkinson's disease. Lancet (London, England). Aug 29 2015;386(9996):896-912.
- 299 doi:10.1016/s0140-6736(14)61393-3
- 300 16. Hautakangas H, Winsvold BS, Ruotsalainen SE, et al. Genome-wide analysis of 102,084 migraine cases
- identifies 123 risk loci and subtype-specific risk alleles. Nature genetics. Feb 2022;54(2):152-160. 301
- doi:10.1038/s41588-021-00990-0 302
- 303 17. Gormley P, Anttila V, Winsvold BS, et al. Meta-analysis of 375,000 individuals identifies 38
- 304 susceptibility loci for migraine. Nature genetics. Aug 2016;48(8):856-66. doi:10.1038/ng.3598
- 305 18. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and
- 306 heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. The Lancet
- 307 Neurology. Dec 2019;18(12):1091-1102. doi:10.1016/s1474-4422(19)30320-5
- 308 19. Hess AS, Abd-Elsayed A. Observational Studies: Uses and Limitations. In: Abd-Elsayed A, ed. Pain: A
- 309 Review Guide. Springer International Publishing; 2019:123-125.
- 310 20. Richmond RC, Davey Smith G. Mendelian Randomization: Concepts and Scope. Cold Spring Harbor
- 311 perspectives in medicine. Jan 4 2022;12(1)doi:10.1101/cshperspect.a040501
- 21. Emdin CA, Khera AV, Kathiresan S. Mendelian Randomization. In: Livingston EH, Lewis RJ, eds. JAMA 312
- Guide to Statistics and Methods. McGraw-Hill Education; 2019. 313
- 22. Lee KJ, Lee SJ, Bae HJ, Sung J. Exploring the causal inference of migraine on stroke: A Mendelian 314
- randomization study. European journal of neurology. Jan 2022;29(1):335-338. doi:10.1111/ene.15101 315
- 316 23. Burgess S, Thompson SG. Avoiding bias from weak instruments in Mendelian randomization studies.
- 317 International journal of epidemiology. Jun 2011;40(3):755-64. doi:10.1093/ije/dyr036
- 318 24. Palmer TM, Lawlor DA, Harbord RM, et al. Using multiple genetic variants as instrumental variables
- 319 for modifiable risk factors. Statistical methods in medical research. Jun 2012;21(3):223-42.
- 320 doi:10.1177/0962280210394459
- 321 25. Auton A, Brooks LD, Durbin RM, et al. A global reference for human genetic variation. Nature. Oct 1
- 322 2015;526(7571):68-74. doi:10.1038/nature15393

- 323 26. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and
- 324 population-based linkage analyses. American journal of human genetics. Sep 2007;81(3):559-75.
- doi:10.1086/519795 325
- 326 27. Bowden J, Spiller W, Del Greco MF, et al. Improving the visualization, interpretation and analysis of
- 327 two-sample summary data Mendelian randomization via the Radial plot and Radial regression.
- 328 International journal of epidemiology. Aug 1 2018;47(4):1264-1278. doi:10.1093/ije/dyy101
- 329 28. Horton MK, Robinson SC, Shao X, et al. Cross-Trait Mendelian Randomization Study to Investigate
- 330 Whether Migraine Is a Risk Factor for Multiple Sclerosis. Neurology. Mar 28 2023;100(13):e1353-e1362.
- doi:10.1212/wnl.0000000000206791 331
- 332 29. Kamat MA, Blackshaw JA, Young R, et al. PhenoScanner V2: an expanded tool for searching human
- 333 genotype-phenotype associations. Bioinformatics (Oxford, England). Nov 1 2019;35(22):4851-4853.
- 334 doi:10.1093/bioinformatics/btz469
- 335 30. Sanderson E, Davey Smith G, Windmeijer F, Bowden J. An examination of multivariable Mendelian
- 336 randomization in the single-sample and two-sample summary data settings. International journal of
- 337 epidemiology. Jun 1 2019;48(3):713-727. doi:10.1093/ije/dyy262
- 31. Bulik-Sullivan B, Finucane HK, Anttila V, et al. An atlas of genetic correlations across human diseases 338
- 339 and traits. Nature genetics. 2015/11/01 2015;47(11):1236-1241. doi:10.1038/ng.3406
- 340 32. Shi H, Kichaev G, Pasaniuc B. Contrasting the Genetic Architecture of 30 Complex Traits from Summary
- 341 Association Data. American journal of human genetics. Jul 7 2016;99(1):139-53.
- 342 doi:10.1016/j.ajhq.2016.05.013
- 33. Shi H, Mancuso N, Spendlove S, Pasaniuc B. Local Genetic Correlation Gives Insights into the Shared 343
- Genetic Architecture of Complex Traits. American journal of human genetics. Nov 2 2017;101(5):737-751. 344
- doi:10.1016/j.ajhq.2017.09.022 345
- 346 34. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set analysis of GWAS data.
- 347 PLoS computational biology. Apr 2015;11(4):e1004219. doi:10.1371/journal.pcbi.1004219
- 348 35. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic
- 349 associations with FUMA. Nature communications. Nov 28 2017;8(1):1826. doi:10.1038/s41467-017-01261-
- 350 5
- 351 36. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science (New York,
- NY). Sep 11 2020;369(6509):1318-1330. doi:10.1126/science.aaz1776 352

- 353 37. Pardiñas AF, Holmans P, Pocklington AJ, et al. Common schizophrenia alleles are enriched in
- 354 mutation-intolerant genes and in regions under strong background selection. Nature genetics. Mar
- 355 2018;50(3):381-389. doi:10.1038/s41588-018-0059-2
- 356 38. Chen J, Zhang C, Wu Y, Zhang D. Association between Hypertension and the Risk of Parkinson's
- 357 Disease: A Meta-Analysis of Analytical Studies. Neuroepidemiology. 2019;52(3-4):181-192.
- 358 doi:10.1159/000496977
- 359 39. Chua SKK, Saffari SE, Lee SJY, Tan EK. Association Between Parkinson's Disease and Coronary Artery
- 360 Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's disease. 2022;12(6):1737-1748.
- 361 doi:10.3233/jpd-223291
- 40. Barbanti P, Fofi L, Aurilia C, Egeo G. Dopaminergic symptoms in migraine. Neurological sciences: 362
- official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 363
- May 2013;34 Suppl 1:S67-70. doi:10.1007/s10072-013-1415-8 364
- 41. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet (London, England). Jun 12 365
- 366 2021;397(10291):2284-2303. doi:10.1016/s0140-6736(21)00218-x
- 367 42. Cabana-Domínguez J, Torrico B, Reif A, Fernàndez-Castillo N, Cormand B. Comprehensive exploration
- 368 of the genetic contribution of the dopaminergic and serotonergic pathways to psychiatric disorders.
- 369 Translational psychiatry. Jan 10 2022;12(1):11. doi:10.1038/s41398-021-01771-3
- 370 43. Toft M, Ross OA. Copy number variation in Parkinson's disease. *Genome medicine*. Sep 6 2010;2(9):62.
- 371 doi:10.1186/gm183
- 44. Özaltun MF, Geyik S, Yılmaz S G. Screening for Copy Number Variations of the 15g13.3 Hotspot in 372
- CHRNA7 Gene and Expression in Patients with Migraines. Current issues in molecular biology. Sep 7 373
- 2021;43(2):1090-1113. doi:10.3390/cimb43020078 374
- 45. Hansen RD, Christensen AF, Olesen J. Family studies to find rare high risk variants in migraine. The 375
- 376 journal of headache and pain. Dec 2017;18(1):32. doi:10.1186/s10194-017-0729-y
- 377 46. Gialluisi A, Reccia MG, Modugno N, et al. Identification of sixteen novel candidate genes for late onset
- 378 Parkinson's disease. Molecular neurodegeneration. Jun 21 2021;16(1):35. doi:10.1186/s13024-021-00455-
- 379 2

Table 1. Univariate Mendelian Randomization to infer the bidirectional relationship between migraine and Parkinson's disease

	N _{SNP}	Methods	OR (95% CI)	<i>p</i> -value	Cochran's Q	<i>p</i> -value for heterogeneity [†]
						or pleiotropy [†]
PD	32	IVW	1.016 (0.908, 1.135)	0.785	35.320	0.271
						0.192
		Weighted median	0.967 (0.828, 1.130)	0.676		
		MR-PRESSO	1.016 (0.908, 1.135)	0.787		
PD	5	IVW	0.944 (0.836, 1.067)	0.358	1.302	0.861
		MR Egger	0.571 (0.189, 1.725)	0.394		0.435
		Weighted median	0.962 (0.828, 1.118)	0.614		
		MR-PRESSO	0.944 (0.881, 1.012)	0.182		
PD	34	IVW	1.006 (0.951, 1.064)	0.846	31.330	0.550
		MR Egger	1.013 (0.887, 1.156)	0.853		0.858
		Weighted median	0.987 (0.910, 1.071)	0.755		
		MR-PRESSO	1.020 (0.959, 1.085)	0.529		
AM	19	IVW	1.003 (0.975, 1.032)	0.817	18.355	0.433
		MR Egger	0.932 (0.851, 1.019)	0.142		0.107
		Weighted median	0.990 (0.950, 1.031)	0.625		
		MR-PRESSO	1.003 (0.975, 1.032)	0.819		
МО	19	IVW	0.956 (0.893, 1.025)	0.207	14.552	0.692
		MR Egger	0.829 (0.692, 0.994)	0.043		0.113
		Weighted median	0.932 (0.845, 1.029)	0.163		
		MR-PRESSO	0.956 (0.899, 1.018)	0.177		
MA	18	IVW	1.032 (0.955, 1.115)	0.430	6.761	0.986
		MR Egger	0.921 (0.764, 1.109)	0.398		0.206
			1.038 (0.932, 1.156)	0.494		
		-				
	PD AM MO	PD 5 PD 34 AM 19 MO 19	MR Egger Weighted median MR-PRESSO PD 5 IVW MR Egger Weighted median MR-PRESSO PD 34 IVW MR Egger Weighted median MR-PRESSO AM 19 IVW MR Egger Weighted median MR-PRESSO AM 19 IVW MR Egger Weighted median MR-PRESSO MR-PRESSO MO 19 IVW MR Egger Weighted median MR-PRESSO MR-PRESSO MA 18 IVW	MR Egger 0.828 (0.602, 1.139) Weighted median 0.967 (0.828, 1.130) MR-PRESSO 1.016 (0.908, 1.135) PD 5 IVW 0.944 (0.836, 1.067) MR Egger 0.571 (0.189, 1.725) Weighted median 0.962 (0.828, 1.118) MR-PRESSO 0.944 (0.881, 1.012) PD 34 IVW 1.006 (0.951, 1.064) MR Egger 1.013 (0.887, 1.156) Weighted median 0.987 (0.910, 1.071) MR-PRESSO 1.020 (0.959, 1.085) AM 19 IVW 1.003 (0.975, 1.032) MR Egger 0.932 (0.851, 1.019) Weighted median 0.990 (0.950, 1.031) MR-PRESSO 1.003 (0.975, 1.032) MO 19 IVW 0.956 (0.893, 1.025) MR Egger 0.829 (0.692, 0.994) Weighted median 0.932 (0.845, 1.029) MR-PRESSO 0.956 (0.899, 1.018) MA 18 IVW 1.032 (0.955, 1.115) MR Egger 0.921 (0.764, 1.109) Weighted median 1.038 (0.932, 1.156)	MR Egger 0.828 (0.602, 1.139) 0.256 Weighted median 0.967 (0.828, 1.130) 0.676 MR-PRESSO 1.016 (0.908, 1.135) 0.787 PD 5 IVW 0.944 (0.836, 1.067) 0.358 MR Egger 0.571 (0.189, 1.725) 0.394 Weighted median 0.962 (0.828, 1.118) 0.614 MR-PRESSO 0.944 (0.881, 1.012) 0.182 PD 34 IVW 1.006 (0.951, 1.064) 0.846 MR Egger 1.013 (0.887, 1.156) 0.853 Weighted median 0.987 (0.910, 1.071) 0.755 MR-PRESSO 1.020 (0.959, 1.085) 0.529 AM 19 IVW 1.003 (0.975, 1.032) 0.817 MR Egger 0.932 (0.851, 1.019) 0.142 Weighted median 0.990 (0.950, 1.031) 0.625 MR-PRESSO 1.003 (0.975, 1.032) 0.819 MO 19 IVW 0.956 (0.893, 1.025) 0.207 MR Egger 0.829 (0.692, 0.994) 0.043 Weighted median 0.932 (0.845, 1.029) 0.163 MR-PRESSO 0.956 (0.899, 1.018) 0.177 MA 18 IVW 1.032 (0.955, 1.115) 0.430 MR Egger 0.921 (0.764, 1.109) 0.398 Weighted median 1.038 (0.932, 1.156) 0.494	MR Egger 0.828 (0.602, 1.139) 0.256 Weighted median 0.967 (0.828, 1.130) 0.676 MR-PRESSO 1.016 (0.908, 1.135) 0.787 PD 5 IVW 0.944 (0.836, 1.067) 0.358 1.302 MR Egger 0.571 (0.189, 1.725) 0.394 Weighted median 0.962 (0.828, 1.118) 0.614 MR-PRESSO 0.944 (0.881, 1.012) 0.182 PD 34 IVW 1.006 (0.951, 1.064) 0.846 31.330 MR Egger 1.013 (0.887, 1.156) 0.853 Weighted median 0.987 (0.910, 1.071) 0.755 MR-PRESSO 1.020 (0.959, 1.085) 0.529 AM 19 IVW 1.003 (0.975, 1.032) 0.817 18.355 MR Egger 0.932 (0.851, 1.019) 0.142 Weighted median 0.990 (0.950, 1.031) 0.625 MR-PRESSO 1.003 (0.975, 1.032) 0.819 MO 19 IVW 0.956 (0.893, 1.025) 0.207 14.552 MR Egger 0.829 (0.692, 0.994) 0.043 Weighted median 0.932 (0.845, 1.029) 0.163 MR-PRESSO 0.956 (0.899, 1.018) 0.177 MA 18 IVW 1.032 (0.955, 1.115) 0.430 6.761 MR Egger 0.921 (0.764, 1.109) 0.398 Weighted median 1.038 (0.932, 1.156) 0.494

[†] p-value for heterogeneity based on Cochran's Q statistic.

382

383

384

385

386

387

Abbreviations: AM: any migraine; CI: confidence interval; MA: migraine with aura; MO: migraine without aura; IVW: inverse variance weighted; OR: odds ratio; PRESSO: Pleiotropy RESidual Sum and Outlier; SNP: Single-nucleotide polymorphism.

[‡] *p*-value or pleiotropy based on MR-Egger regression intercept.

390

391

	0	Model	IVW		MR-Egger		Weight median		MR-PRESSO	
Exposure	Outcome	Model	OR (95% CI)	<i>p</i> -value						
AM	PD	a	0.993(0.895, 1.102)	0.897	0.992(0.894, 1.101)	0.879	0.973(0.836, 1.132)	0.723	0.993(0.895, 1.102)	0.897
		b	1.024(0.906, 1.158)	0.702	0.856(0.602, 1.218)	0.388	0.939(0.796, 1.108)	0.459	1.024(0.906, 1.159)	0.705
МО	PD	a	0.942(0.857, 1.034)	0.207	0.944(0.859, 1.037)	0.225	0.940(0.831, 1.063)	0.325	0.942(0.859, 1.033)	0.204
		b	0.934(0.826, 1.057)	0.278	0.928(0.819, 1.051)	0.240	0.909(0.766, 1.080)	0.279	0.934(0.884, 0.988)	0.076
MA	PD	a	0.996(0.931, 1.066)	0.902	0.995(0.930, 1.065)	0.888	1.018(0.926, 1.121)	0.711	0.996(0.930, 1.066)	0.902
		b	1.048(0.978, 1.124)	0.181	1.069(0.999, 1.146)	0.053	1.022(0.920, 1.135)	0.679	1.049(0.978, 1.124)	0.187
PD	AM	a	0.964(0.915, 1.015)	0.168	1.001(0.942, 1.065)	0.962	0.984(0.944, 1.026)	0.444	0.964(0.915, 1.016)	0.170
		b	0.994(0.957, 1.033)	0.761	0.987(0.952, 1.023)	0.477	1.009(0.967, 1.054)	0.677	0.994(0.957, 1.033)	0.764
PD	МО	a	0.948(0.861, 1.045)	0.287	0.959(0.868, 1.061)	0.420	0.929(0.840, 1.026)	0.148	0.949(0.861, 1.045)	0.288
		b	0.991(0.925, 1.062)	0.794	0.990(0.921, 1.064)	0.790	0.967(0.869, 1.075)	0.524	0.991(0.926, 1.060)	0.791
PD	MA	a	1.021(0.926, 1.127)	0.669	1.004(0.908, 1.111)	0.939	1.040(0.931, 1.162)	0.491	1.022(0.926, 1.127)	0.670
		b	1.043(0.964, 1.129)	0.294	0.999(0.984, 1.014)	0.883	1.052(0.938, 1.181)	0.384	1.043(0.964, 1.129)	0.307

^a adjusted for coronary heart disease; ^b adjusted for hypertension.

Abbreviations: AM: any migraine; CI: confidence interval; MA: migraine with aura; MO: migraine without aura; IVW: inverse variance weighted; OR: odds ratio;

PRESSO: Pleiotropy RESidual Sum and Outlier.



Fig 1. MR leave-one-out analyses of migraine on Parkinson's disease (above) and Parkinson's disease on migraine (below).

Fig 2. Local genetic correlation and genetic covariance between any migraine and Parkinson's disease, and also local SNP heritability estimation for migraine and Parkinson's disease respectively.

Fig 3. Tissue-type enrichments of AM and PD GWAS associations. The red dashed line is the Bonferroni corrected significant level. Tissues that showed significant enrichment (corrected P < 0.05) are shown in yellow. AM = Any migraine; PD = Parkinson's disease.





